Summary
This Mendelian randomisation study examined whether the cardiovascular benefit of lowering LDL cholesterol depends on the biological mechanism by which it is lowered, using genetic variants in CETP and HMGCR genes as natural experiments. In a cohort of over 102,000 participants with external validation in nearly 190,000 more, CETP variants associated with raised HDL-C and lower LDL-C (and apoB) showed cardiovascular protection comparable to statin-induced LDL reduction, suggesting that different pathways to LDL reduction may confer similar clinical benefit.
Regional applicability
The study includes cohort and case-control data from the United Kingdom, and the findings are therefore directly applicable to UK population genetics and cardiovascular risk assessment. The genetic variants studied are common across European ancestry populations, making the results broadly transferable to UK clinical and public health contexts.
Key measures
Odds ratios for major cardiovascular events; HDL-C, LDL-C, and apoB levels; CETP and HMGCR genetic scores
Outcomes reported
The study measured the association between genetic variants in CETP and HMGCR genes, changes in lipoprotein levels (HDL-C, LDL-C, apoB), and risk of major cardiovascular events. Findings were validated across multiple cohort and case-control studies in North America and the United Kingdom.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.